While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Alkermes plc (ALKS) reiterated its revenue guidance for the full-year 2024.
For fiscal 2024, the company continues to project total revenues between $1.50 billion and $1.60 billion. It also expects net income in a range of $350 million to $390 million and adjusted net income in a range of $465 million to $505 million.
On average, analysts polled by Thomson Reuters expect the company to report revenues of $1.50 billion for the year. Analysts\' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com